Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press141310.17650/1726-9776-2020-16-4-129-135DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыEfficacy and safety of radium-223 in routine clinical practiceЭффективность и безопасность радия-223 в исследованиях реальной клинической практикиhttps://orcid.org/0000-0001-7748-9527MatveevV. B.МатвеевВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-3172-2909MarkovaA. S.МарковаА. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Анна Сергеевна Маркова

115478 Москва, Каширское шоссе, 24

mark-an1@ya.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России301220201641291351002202110022021https://oncourology.abvpress.ru/oncur/article/view/1413

Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.

В настоящее время в реальной клинической практике есть ряд возможностей для лечения больных метастатическим кастрационно-резистентным раком предстательной железы. Однако четкие стандарты последовательного применения зарегистрированных препаратов пока не определены. Целенаправленно воздействуя на очаги метастазов в кости, радий-223 представляет собой одну из лечебных опций при кастрационно-резистентном раке предстательной железы с костными метастазами, включенную в зарубежные и национальные рекомендации по лечению рака предстательной железы. В статье представлены результаты применения радия-223 у пациентов с метастатическим кастрационно-резистентным раком предстательной железы в зарубежных неинтервенционных клинических исследованиях, проведенных в условиях реальной клинической практики. В них радий-223 подтвердил эффективность и безопасность, продемонстрированные ранее в исследовании ALSYMPCA. В ряде протоколов показатели общей выживаемости, симптоматических скелетных событий и частоты развития нежелательных явлений были лучше, чем по результатам регистрационного исследования.

radium-223metastatic castration-resistant prostate cancerroutine clinical practiceabirateroneenzalutamidedocetaxelрадий-223метастатический кастрационно-резистентный рак предстательной железыреальная клиническая практикаабиратеронэнзалутамиддоцетакселBubendor F.L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-83. DOI: 10.1053/hp.2000.6698.Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270-3. DOI: 10.1016/j.eururo.2013.10.055.Mottet N., Cornford P., van der Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate cancer (2020). Available at: https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020v4.pdf.Schaeffer E., Srinivas S., Antonarakis E. et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) -prostate cancer (version 3.2020) (2020). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.Clinical Guidelines of the Russian Association of Oncologists for the treatment of patients with prostate cancer 2020. Available at: https://oncology-association.ru/wp-content/uploads/2020/09/rak_predstatelnoj_zhelezy.pdf. (In Russ.).Клинические рекомендации Ассоциации онкологов России по лечению пациентов с раком предстательной железы 2020. Доступно по: https://oncology-association.ru/wp-content/uploads/2020/09/rak_predstatelnoj_zhelezy.pdf.Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. DOI: 10.1056/NEJMoa1213755.Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-406. DOI: 10.1016/S1470-2045(14)70474-7.Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castrationresistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306-16. DOI: 10.1016/S1470-2045(16)30173-5.Higano C.S., Saad F., Sartor A.O. et al. Clinical outcomes and patient (pt) profiles in REASSURE: an observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38(6_suppl):32. DOI: 10.1200/JCO.2020.38.6_suppl.32.Clinical Guidelines “Prostate cancer” of the Russian Ministry of Health 2020. Available at: http://cr.rosminzdrav.ru/#!/recomend/99. (In Russ.).Клинические рекомендации «Рак предстательной железы» Минздрава России 2020. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/99.Higano C.S., Harshman L.C., Dizdarevic S. et al. Safety and overall survival (OS) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. J Clin Oncol 2020;38 (15_suppl):5542.Dizdarevic S., Petersen M.D., Essler M. et al. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in nonintervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imag 2019;46:1102-10. DOI: 10.1007/s00259-019-4261-y.Smith M., Parker C., Saad F. et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. DOI: 10.1016/S1470-2045(18)30860-X.European Medicines Agency (EMA). EMA restricts use of prostate cancer medicine Xofigo. 2018. Available at: https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo.Shore N.D., Tutrone R.F., Mariados N.F. et al. eRADicAte: a prospective evaluation combining radium-223 dichloride and abiraterone acetate plus prednisone in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2018;16(2):149-54. DOI: 10.1016/j.clgc.2017.10.022.Shore N., Higano C.S., George D.J. et al. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2020;23:680-8. DOI: 10.1038/s41391-020-0236-0.Poeppel T., Eschmann S., Werner A. et al. 828 P Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): an interim review of a prospective, noninterventional study (PARABO). Annal Oncol 2020;29(Suppl 8):VIII289-90. DOI: 10.1093/annonc/mdy284.037.Sternberg C.N., Saad F., Graff J.N. et al. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Ann Oncol 2020;31(2):257-65. DOI: 10.1016/j.annonc.2019.10.025.Sartor O., Vogelzang N.J., Sweeney C. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist 2018;23(2):193-202. DOI: 10.1634/theoncologist.2017-0413.https://clinicaltrials.gov/ct2/show/NCT02194842.https://clinicaltrials.gov/ct2/show/NCT03574571.